Neola Medical Ab · OMXSTO:NEOLA
Neola Medical Ab — Q4 2024 Earnings Presentation
29 slides from Neola Medical Ab's earnings presentation, Feb 12, 2025
Slide 1: Q4 2024
Q4 2024 Published February 12, 2025 ”Having achieved key milestones in 2024, we now enter the clinical phase with approval to initiate the first clinical study with Neola® on preterm born babies in neonatal care.” CEO Hanna Sjöström Neola Medical Q4, 2024
Slide 2: Neola Medical Presentation: CEO and CFO
Neola Medical Presentation, Hanna Sjöström David Folkesson CEO CFO Neola Medical since 2019 Neola Medical since 2024 2 Neola Medical Q4, 2024
Slide 3: Forward looking statements
Forward looking statements This presentation and our discussion include forward-looking statements regarding our business strategies, market opportunities, anticipated financial performance, product development, and other related topics. These statements involve inherent risks and uncertainties, inc
Slide 4: Instant detection of pulmonary complications for proactive care
Instant detection of pulmonary complications for proactive care, reduced morbidity and improved quality of life Neola Medical Q4, 2024
Slide 5: Founded in 2016 based on advanced research at Lund University
2016 10 2 2026 Founded in 2016 based HQ Ideon Gateway in Late-stage development Aiming for FDA on advanced research at Lund with 10 employees of class II medical device application in 2026 Lund University 5 Neola Medical Q4, 2024
Slide 6: Neola Medical - a Stanford Impact Company
Neola Medical - a Stanford Impact1 Company Neola® is selected as one of the most promising innovations in neonatal intensive care Neola Medical Q4, 2024
Slide 7: Great clinical support for Neola
Great clinical support for Neola® “I actually really love this as a neonatologist because a lot of what I see are either pneumothorax where a lung can collapse, and we don't notice it until the vital signs change. X-rays aren’t always that helpfully. So really understanding oxygenation as well as ho
Slide 8: Current standard of care in need of new technology
Current standard of care in need of new technology Current monitoring methods are insufficient Monitoring method with Neola® - Snapshots of lung status - Continuous monitoring of lungs in real-time - Slow - Instant - Invasive - Non-invasive - Non-radiation Pulse oximetry Blood sampling X-ray EIT Ult
Slide 9: 1 in 10 babies are born preterm every year
1 in 10 babies are born preterm every year Early detection of pulmonary complications is key to avoid costly complications 1.1 million <5 years 1st cause 50 % Preterm born babies die Most common cause of Respiratory failure Of very and extremely every year death of children <5 leading cause of death
Slide 10: Growing and non-cyclical market
Growing and non-cyclical market Neola Medical is well positioned to benefit from favourable market trends Global neonatal respiratory device market USD million 3,001 2,816 Growing number of patients 2,662 Increase in preterm births worldwide, leading to more children 2,534 developing RDS or other lu
Slide 11: Huge addressable market with one Neola per baby
Huge addressable market with one Neola® per baby France United Kingdom 57,000 2,547 53,887 Preterm NICU care 1,782 babies places Preterm NICU care babies places Germany United States 66,752 Preterm 2,140 NICU care babies places ▪ Focus market due to large number of newborns and the particularly high
Slide 12: Revenue streams
Revenue streams Include sales of device, disposables and service agreement One Neola® unit per baby/bed Daily change of disposable Service agreement revenue probes Neola Medical Source: BasedQ4, on2024 Pricing project findings by MCRA 2022 incl. field market research of 40 providers, 20 neonatologis
Slide 13: 10 leading children's hospitals with NICUs
10 leading children’s hospitals with NICUs Target customers for market launch-800 beds Top 10 target pilot hospitals (# NICU beds) Pittsburgh (77) (40) Cincinnati (59) (35) Logo SF (50) Philadelphia (100) LA (91) Washington, DC (55) Columbus (130) Houston (173) • Source: 13 Neola MedicalAmerican Q4,
Slide 14: Financial value to customers with Neola
Financial value to customers with Neola® Include avoided costs and reduced length–of–stay Reduced length of stay in the NICU Reduced number of blood gas samples and chest x-rays Reduced manual observation time for nurses Potential reimbursement via MS-DRG payments Neola Medical Source: BasedQ4, on20
Slide 15: Focus 2024
Focus 2024 Preparations for 1 Clinical validation 2 FDA process 3 market launch in the U.S 15 Neola Medical Q4, 2024
Slide 16: Reaching Milestones that Drive Value Creation
Reaching Milestones that Drive Value Creation Scientific evidence Product Clinical study FDA application Neola® meets partial Positive clinical results Subsidiary in regulatory requirements from Irish independent the USA for FDA approval study of 100 newborns Clinical study on preterm born babies in
Slide 17: Full year 2024: Advancing to clinical phase
Full year 2024 1. Advancing to clinical phase Obtianed CB certificate, achieving milestone that meets partial regulatory requirements for FDA approval Concluded Human Factors Validation Study with nurses in the U.S., instrumental for FDA market approval application Announced first pivotal clinical s
Slide 18: Full year 2024: Importance of market activity and preparations in the U.S.
Full year 2024 2. Importance of market activity and preparations in the U.S. Silver medal winner in Stanford Pediatric Device Consortium (PDC) Accelerator Pitch Competition 2024 Prominent role at largest and most prestigious scientific gatherings outside the U.S. U.S. professor in neonatology recogn
Slide 19: Full year 2024: Strengthened competitive position
Full year 2024 3. Strengthened competitive position Patent Grants in the U.S. and Europe Reinforcing the Protection of the Company’s Innovation Pipeline Safeguarding Market Leadership 19 Neola Medical Q4, 2024
Slide 20: Significant event Q4 2024: Neola logo trademarked in the U.S.
Significant event Q4 2024 1. Neola® logo trademarked in the U.S. Intellectual property in our most important market Cornerstone of our commercialization strategy Strenghened position in neonatal market ahead of market launch in the U.S. 20 Neola Medical Q4, 2024
Slide 21: Significant event Q4 2024: Approval of clinical study
Significant event Q4 2024 2. Approval of clinical study First clinical study on preterm born babies in Sweden Achieved milestone for very first evaluation of Neola® in its target patient group Meeting high regulatory standards in our journey to improve neonatal care and save lives 21 Neola Medical Q
Slide 22: Clinical pilot study in Sweden
Clinical pilot study in Sweden The study will evaluate the safety and performance of Neola® in preterm born babies Neonatal intensive care unit at a Swedish hospital 10 preterm born babies from 28 weeks gestational age and weight between 1000-3000 grams Neola Medical Q4, 2024
Slide 23: Financial summary
Financial summary 23 Neola Medical Q4, 2024
Slide 24: Financials
Financials Fourth quarter, October-December 2024 Year report, January-December 2024 Summary Summary Operating income: SEK 0k (0) Operating income: SEK 0k (0) Operating result: SEK -2 759k (-2 139) Operating result: SEK -10 814k (-9 621) The period’s cash flow: SEK -4 606k (-5 036) The period’s cash
Slide 25: About the share
About the share Share capital, shareholders and the share 2024-12-31 Shareholders 2024-12-31 (Top 10) Amount of shares Percentage of capital Percentage of votes As of December 31st, 2024, Neola Medical’s share capital was 5 010 751,19 SEK ANMIRO AB 17 647 246 25,3% 25,3% with a total of 70 150 234 s
Slide 26: Focus 2025
Focus 2025 Continued market 1 Clinical studies 2 Regulatory process 3 preparations in the U.S 26 Neola Medical Q4, 2024
Slide 27: Financial calendar and contact
Financial calendar and contact 9 21 22 6 April 2025 May 2025 Aug 2025 Nov 2025 Annual report 2024 Q1 report 2025 and Annual Q2 report 2025 Q3 report 2025 General Assembly in Lund Financial reports Questions about the report is answered by: Financial reports are available at www.neolamedical.se | Han
Slide 28: Investment highlights
Investment highlights 1 Large and growing addressable market 2 Great clinical need and demand 3 Attractive business model 4 Proven technology 5 Highly experienced team 28 Neola Medical Q4, 2024
Slide 29: LinkedIn I Facebook I Website
LinkedIn I Facebook I Website Neola Medical Q4, 2024